Disufenton Sodium

Disufenton Sodium had been in phase III clinical trials for the treatment of stroke. This compound was originally discovered by Renovis (acquired by Evotec in 2008), then licensed and developed by AstraZeneca in collaboration with Otologic Pharmaceutics. However, this study was discontinued.

General Information

Update Date:2016-02-24

Drug Name:
Disufenton Sodium
Research Code:
NXY-059; Disufenton Sodium; ARL-16556; CPI-22; CXY-059; HPN-07; OKN-007
Trade Name:
MOA:
Indication:
Stroke
Status:
Phase III (Discontinued)
Company:
Evotec (Originator) , AstraZeneca,Otologic
Sales:
ATC Code:
Chemical Structure

Update Date:2015-12-08

Molecular Weight 381.33
Formula C11H13NO7S2▪2Na
CAS No. 168021-77-0 (Disufenton);
168021-79-2 (Disufenton sodium);
Chemical Name 1,3-Benzenedisulfonic acid, 4-[[(1,1-dimethylethyl)oxidoimino]methyl]-, sodium salt (1:2)
Disufenton (Free Acid/Base)Parameters:
MW HD HA FRB* PSA* cLogP*
337.37 2 8 4 154 -3.249±0.747
*:Calculated by ACD/Labs software V11.02.
Synthesis & Impurities

Update Date:2016-04-08


1. US5488145.

2. US5780510.


Impurity database is being updated!